HRP20090009T3 - N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors - Google Patents

N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Info

Publication number
HRP20090009T3
HRP20090009T3 HR20090009T HRP20090009T HRP20090009T3 HR P20090009 T3 HRP20090009 T3 HR P20090009T3 HR 20090009 T HR20090009 T HR 20090009T HR P20090009 T HRP20090009 T HR P20090009T HR P20090009 T3 HRP20090009 T3 HR P20090009T3
Authority
HR
Croatia
Prior art keywords
alkyl
aryl
group
heteroaryl
substituted
Prior art date
Application number
HR20090009T
Other languages
English (en)
Croatian (hr)
Inventor
R. V. Finlay Maurice
Waterson David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20090009T3 publication Critical patent/HRP20090009T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20090009T 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors HRP20090009T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20090009T3 true HRP20090009T3 (en) 2009-02-28

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090009T HRP20090009T3 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Country Status (33)

Country Link
US (1) US7485644B2 (https=)
EP (1) EP1644340B1 (https=)
JP (1) JP4701167B2 (https=)
KR (1) KR20060026440A (https=)
CN (2) CN1812974B (https=)
AR (1) AR044931A1 (https=)
AT (1) ATE414063T1 (https=)
AU (1) AU2004251104B2 (https=)
BR (1) BRPI0411929A (https=)
CA (1) CA2529468A1 (https=)
CO (1) CO5650254A2 (https=)
CY (1) CY1108757T1 (https=)
DE (1) DE602004017733D1 (https=)
DK (1) DK1644340T3 (https=)
ES (1) ES2315675T3 (https=)
HR (1) HRP20090009T3 (https=)
IL (1) IL172615A0 (https=)
IS (1) IS8257A (https=)
MX (1) MXPA05013460A (https=)
MY (1) MY138680A (https=)
NO (1) NO20060444L (https=)
NZ (1) NZ544208A (https=)
PL (1) PL1644340T3 (https=)
PT (1) PT1644340E (https=)
RU (1) RU2351595C2 (https=)
SA (1) SA04250224B1 (https=)
SE (1) SE0301922D0 (https=)
SI (1) SI1644340T1 (https=)
TW (1) TW200524898A (https=)
UA (1) UA81491C2 (https=)
UY (1) UY28387A1 (https=)
WO (1) WO2005000822A1 (https=)
ZA (1) ZA200510458B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
WO2007048788A1 (en) * 2005-10-26 2007-05-03 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2012005229A1 (ja) * 2010-07-08 2012-01-12 科研製薬株式会社 Ｎ－ヒドロキシホルムアミド誘導体およびそれを含有する医薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU735929B2 (en) * 1998-01-30 2001-07-19 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
WO2001062742A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003091247A2 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004113312A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
AR044931A1 (es) 2005-10-12
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
MY138680A (en) 2009-07-31
ATE414063T1 (de) 2008-11-15
PL1644340T3 (pl) 2009-04-30
TW200524898A (en) 2005-08-01
PT1644340E (pt) 2009-01-02
CO5650254A2 (es) 2006-06-30
KR20060026440A (ko) 2006-03-23
US20070197542A1 (en) 2007-08-23
EP1644340A1 (en) 2006-04-12
CA2529468A1 (en) 2005-01-06
HK1086835A1 (en) 2006-09-29
EP1644340B1 (en) 2008-11-12
CN1812974B (zh) 2011-06-29
RU2351595C2 (ru) 2009-04-10
SE0301922D0 (sv) 2003-06-27
DE602004017733D1 (de) 2008-12-24
CY1108757T1 (el) 2014-04-09
ES2315675T3 (es) 2009-04-01
DK1644340T3 (da) 2009-02-02
AU2004251104A1 (en) 2005-01-06
US7485644B2 (en) 2009-02-03
RU2005141058A (ru) 2006-07-27
IS8257A (is) 2006-01-23
JP2007516164A (ja) 2007-06-21
UY28387A1 (es) 2005-01-31
JP4701167B2 (ja) 2011-06-15
WO2005000822A1 (en) 2005-01-06
CN102229589A (zh) 2011-11-02
MXPA05013460A (es) 2006-03-09
IL172615A0 (en) 2006-04-10
SI1644340T1 (sl) 2009-02-28
AU2004251104B2 (en) 2008-05-08
BRPI0411929A (pt) 2006-08-15
UA81491C2 (en) 2008-01-10
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
CN1812974A (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
HRP20080236T3 (en) Quinoline derivatives as phosphodiesterase inhibitors
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
HRP20080120T3 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
AR011623A1 (es) Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos.
DK0402644T3 (da) N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
BRPI0211844B8 (pt) composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
CO5011090A1 (es) Derivados de acil-piperazinil-pirimidinas, procedimiento para su preparacion y composiciones farmaceuticas de los mismos
AR015512A1 (es) Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica
HRP20040977B1 (hr) Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji
HRP20080431T3 (en) Novel dicarboxylic acid derivatives
YU39698A (sh) Hinoksalindioni
FI832648A0 (fi) Dihydropyridiner som antiischemiska och antihypertensiva laekemedel
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
HRP20080490T3 (en) 3-fluoro-piperidines as nmda/nr2b antagonists
BR112022002674A2 (pt) Derivado de 2-aminoquinazolinona
HRP20090009T3 (en) N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
DE60130766D1 (de) Serotoninwiederaufnahme-inhibitoren
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives
DK0962457T3 (da) Piperidoner som tachykininantagonister
GB1455987A (en) Pyrido 1,2-a- pyrimidinone derivatives useful as pharmaceuticals
SE0303220D0 (sv) New process
BR112022021920A2 (pt) Síntese de compostos heterocíclicos
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b